A compound studied for libido, sexual response, and arousal. Acts on the brain rather than through blood vessels, distinguishing it from medications that work by increasing blood flow.
Compound overview
What it is
PT-141 (bremelanotide) is a cyclic peptide analogue of the melanocortin peptide alpha-MSH. It acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, and MC4R in the central nervous system. MC4R activation in the hypothalamus and limbic system directly increases sexual desire and arousal — it acts upstream of the vascular mechanism that PDE5 inhibitors (such as sildenafil) target. This means it is effective in cases where blood flow is not the limiting factor and it works in both males and females.
Sexual desire and arousal increase — the effect is centrally mediated rather than peripheral. In women, genital arousal and desire increase. In men, spontaneous erections are commonly reported. The onset is typically 45–90 minutes post-nasal administration and duration 6–12 hours. Tanning (melanin stimulation) is a side effect from MC1R activity.
Studied outcomes
- FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women
- Improved sexual desire and arousal scores in male and female clinical trials
- Spontaneous erections in men at doses above 1mg in early trials
- Central mechanism confirmed — distinct from PDE5 inhibitors
- Significant improvement in sexual distress and satisfaction scores
Suitability
Who it's for
- Low libido and sexual desire — both male and female
- Hypoactive sexual desire disorder (HSDD)
- Sexual dysfunction with a central (neurological) rather than vascular component
- Performance anxiety contributing to desire or arousal issues
Who should avoid it
- Pregnancy
- Active cardiovascular disease — transient blood pressure elevation occurs
- Those on antihypertensives — additive blood pressure lowering effect
- Those with history of melanoma or atypical moles — melanocortin receptor stimulation is a theoretical concern
Dosing guidance
Protocol guidance
Dose
0.75–1.75mg per use (standard), administered 45 minutes before intended activity
Frequency
As needed — not for daily use
Cycle length
As needed; no defined cycle required
Route
Intranasal spray — bottle included
Timing
45–90 minutes before intended activity
Safety
Contraindications & cautions
- Nausea is the most common side effect — particularly at doses above 1.75mg; administer on a light stomach
- Flushing and transient blood pressure elevation occur — sit down for 30 minutes post-dose
- Tanning is a secondary effect — melanin production activates with repeated use
- Do not use more frequently than every 48–72 hours
- Not for use with antihypertensive medications without physician clearance
Stacking
Pairs well with
Both act on melanocortin receptors — PT-141 for libido, Melanotan II for tanning; not typically combined due to overlapping side effects
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.